MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2026.07.009

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2026

Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US.

Blue Brandon J, ElHabr Andrew K, Derman Benjamin A, Ray Avik, Ting Jie, Hasegawa Ken, Elsisi Zizi, Farajkhah Kian, Ayer Turgay, Suvannasankha Attaya

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Chimeric antigen receptor (CAR) T-cell therapies offer substantial survival benefits for relapsed and/or refractory multiple myeloma (RRMM). However, access remains limited across the US. We examined geographic variation in MM burden and key drivers of CAR T access disparities to inform targeted strategies to close these gaps.

PATIENTS AND

METHODS

Patients with MM and CAR T recipients from January 2021-August 2024 were identified from the Komodo Patient-Level Analytics and Insights Derivative claims database. MM prevalence at the ZIP-3 level came from the US Cancer Statistics database. Drive-times to the nearest authorized treatment center (ATC) for patients with MM and to ATCs for CAR T recipients were calculated and compared nationally and by region.

RESULTS

There were 106,593 prevalent patients over the study period. The South had the second highest MM burden (66.1/100,000 people) but the lowest proportion of patients within 1 hour of an ATC (55.7%). CAR T recipients in the South also traveled the longest to their ATC (median, 1.5 hours). Multivariable analysis with socio-economic and demographic covariates indicated that ≥ 2 hour potential drive-time to nearest ATC versus < 1 hour (adjusted odds ratio [or] = 0.43; 95% confidence interval (CI), 0.27-0.69), household income < $50k versus ≥ $100k (or = 0.19; 95% CI, 0.05-0.69), and residence in nonmetropolitan areas versus metropolitan (or = 0.41; 95% CI, 0.28-0.60) were significantly associated with reduced odds of CAR T use.

CONCLUSIONS

There were substantial geographic and socioeconomic disparities in CAR T access, with long drive‑times, lower household income, and non‑metro residence limiting uptake and underscoring the need for targeted ATC expansion.

Для цитирования: Blue Brandon J, ElHabr Andrew K, Derman Benjamin A, Ray Avik, Ting Jie, Hasegawa Ken, Elsisi Zizi, Farajkhah Kian, Ayer Turgay, Suvannasankha Attaya. Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US.. Clinical lymphoma, myeloma & leukemia. 2026. DOI: 10.1016/j.clml.2026.07.009.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.